Dyadic International, Inc. (DYAI) Stock Score, Valuation & Financial Research
Dyadic International, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 15/100.
Quick answer for DYAI
Dyadic International, Inc. currently has a Wall Street Score of 15/100. The stored market price is $0.42. Its financial score is 12/100. Its valuation score is 0/100. The latest WSS change is -0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Dyadic International, Inc. does
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products. These offerings span a wide range of biological therapeutics, including virus-like particles (VLPs), antigens, monoclonal, bi-specific, and tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and diverse therapeutic enzymes and proteins. A key pipeline asset is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate. This candidate is currently slated for a
DYAI financial snapshot
- Wall Street Score:
- 15/100
- Current price:
- $0.42
- Market capitalization:
- $15.1M
- Revenue:
- $3.5M
- Net income:
- $-7.6M
- Free cash flow:
- $-5.7M
- Cash:
- $1.4M
- Total debt:
- $5.0M
- EPS:
- -0.21
- Financial score:
- 12/100
- Valuation score:
- 0/100
- Revenue score:
- 22/100
What stands out
- Reported year-over-year revenue growth is +1.8%.
- Free cash flow is $-5.7M, showing cash burn in the current stored period.
- The balance sheet shows $1.4M of cash versus $5.0M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -0.1 points: DYAI decreased 0.1 points because some fundamentals weakened.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-06.
How to research DYAI
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.